How to Buy Immunocore Holdings Stock
Immunocore Holdings PLC
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases.
Immunocore Holdings stock last closed at $34.68, down 2.67% from the previous day, and has decreased 12.62% in one year. It has overperformed other stocks in the Biotechnology industry by 0.64 percentage points. Immunocore Holdings stock is currently +49.81% from its 52-week low of $23.15, and -16.51% from its 52-week high of $41.54.
There are currently 50.23M IMCR shares outstanding. The market capitalization of IMCR is $1.74B. In the last 24 hours, 435,000 IMCR shares were traded.
How to Buy Immunocore Holdings Stock
Wondering how to invest in Immunocore Holdings stock? Here's how.
- Figure out where to buy Immunocore Holdings stock: You need to choose a stock brokerage, but don't worry - we've tried dozens of stock brokerages and apps to help you figure out where to buy Immunocore Holdings stock.
- Open a brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've found.
- Deposit funds into your investment account: Select your method of payment and add your information.
- Analyze Immunocore Holdings stock: The Immunocore Holdings ticker symbol is IMCR. Is Immunocore Holdings stock a good investment? Should you buy shares of IMCR? How do IMCR's underlying business fundamentals look? Do top analysts think Immunocore Holdings is a good buy? Why has IMCR's stock price moved recently? (Hint: Our stock analysis website can help you evaluate if IMCR is a good stock to buy).
- Make your IMCR buy order: Decide if you will purchase IMCR shares at the current market price or use a limit order to purchase IMCR shares at a particular price.
- Keep an eye on your IMCR investment: Create a watchlist to keep track of your investment in Immunocore Holdings shares.
Step 1: Figure out where to buy Immunocore Holdings stock
You will need a brokerage account in order to access the NASDAQ market and buy IMCR stock.
Our favorite brokerage: eToro
Based on our experience, eToro is the best place to buy stocks. eToro gives you:
- You can invest in stocks with 0% commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still invest in the stock.
- Access to global markets: From Technology to Financial Services, New York to Shanghai (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's top stock exchanges.
- Social investing: eToro has a community with more than 20 million users globally. Talk to, learn from, and copy the unique crypto portfolios of other investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other assets: Such as ETFs and cryptos.
Get $10 towards your stock purchase by creating an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Open a brokerage account
Now that you've picked the best brokerage, it's time to fill out some personal information so you are able to buy IMCR stock today.
How to Create a New Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal data to open your new brokerage account.
- Send your details by pressing the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your investment account
Now that you have finished signing up on one of the most highly reviewed stock market apps, your next step is to transfer the money for your investment:
Check out the walkthrough below if you need help depositing funds into your investment account.
Step 4: Analyze Immunocore Holdings stock
After you have decided on the best place to buy Immunocore Holdings stock, it's important to evaluate their stock before you invest, so you actually wrap your head around the risk as well as the opportunity.
Immunocore Holdings stock quick numbers
IMCR Due Diligence Score
WallStreetZen was built to help average investors do more accurate fundamental analysis quickly.
You can view all of the due diligence checks on IMCR's stock page.
Is IMCR stock overvalued?
You can use many financial metrics, analyses, models, and charts to gauge IMCR's intrinsic value.
Using relative valuations measures:
- IMCR could be undervalued based on its P/B ratio of 4.6x, relative to Biotechnology industry P/B ratio of 4.66x
You can do additional valuation research on IMCR's stock here.
IMCR Financials at a glance
Signs that IMCR is financially healthy:
- There are more short-term assets than short-term liabilities on the IMCR balance sheet.
- There are more short-term assets than long-term liabilities on the IMCR balance sheet.
- IMCR profit margin has gone up from -22.7% to -6.5% in the past year.
Signs that IMCR is not financially healthy:
- IMCR's operating cash flow of $31.08M allows it to safely service it's debt of $434.00M.
- IMCR has a relatively high debt to equity ratio of 1.72.
- IMCR earnings of -$4.14M is not sufficient to cover its interest payments.
Is it a good time to buy IMCR stock, according to analysts?
Out of 6 Wall Street analysts who research IMCR, the consensus analyst rating on IMCR is a Buy
It's important to note that analyst ratings are not recommendations, nor are they financial advice.
Latest IMCR Analyst Upgrades/Downgrades
Andrew Galler, a bottom 8% analyst from Morgan Stanley assumes IMCR with a hold rating and maintains their IMCR price target from $35.00 to $35.00, on Mar 7, 2025.
You can dig deeper into what analysts are projecting on the Immunocore Holdings stock forecast page.
IMCR Momentum
IMCR Earnings
Last year, IMCR revenue was $333.58M. Over the past 4 year, IMCR's revenue has gone up by 72.51% per year. This was faster than the Biotechnology industry average of 43.24%.
Find out more about IMCR's earnings and revenue performance here.
Who is buying/selling IMCR?
In the past 12 months, insiders at IMCR have bought more shares than they have sold.
Baker Bros Advisors LP, Director of IMCR, was the latest IMCR insider to buy. They bought $1,787,791.62 worth of IMCR shares on Mar 17, 2025.
Research more about who owns IMCR stock here.
Does IMCR provide a stable income stream?
No, Immunocore Holdings doesn't provide an income stream by paying out dividends.
What do other investors have to say about IMCR?
One of the primary reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to learn what other investors have to say.
Step 5: Make your IMCR buy order
There are two main options:
- Market order: A market order is an order to buy or sell a stock at the best possible price.
Market orders are usually fine. - Limit order: A limit order enables you to buy or sell a security at a specific price (or better).
If you want to be sure you're buying or selling at a particular price, place a limit order.
Hit the Open button and your broker will execute the order.
If you require more help with investing in stocks on eToro, watch the how to video below:
Step 6: Keep an eye on your IMCR investment
Now that you own some IMCR shares, you'll want to keep up with your new company.
Put IMCR on a watchlist to see the latest developments about your IMCR stock.
IMCR Feed
How to Buy Stock in Immunocore Holdings
To summarize, here are the 6 steps for buying Immunocore Holdings stock:
- Figure out where to buy Immunocore Holdings stock
- Open a brokerage account
- Deposit funds into your investment account
- Analyze Immunocore Holdings stock
- Make your IMCR buy order
- Keep an eye on your IMCR investment
If you need a online brokerage, eToro is our favorite option.
Get Started with eToro TodayIf you would like to monitor your new investment in Immunocore Holdings, hit the button below to create your watchlist.
Other "How To" Guides You May Enjoy
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.